CellFE to Participate in NIIMBL Funded Project
CellFE will participate in one of 15 funded projects as part of $9M in funding by the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) and funds contributed by participating organizations. These projects were selected from the pool of proposals submitted in response to NIIMBL’s Project Call 2.2 announced on November 30, 2018. The call for proposals solicited innovative concepts addressing shared technology challenges and workforce gaps in the biopharmaceutical industry.
Project Details
Scalable Microfluidics that Can Address the Challenge of Delivery of Large Transgenes to Therapeutic Cells
Lead: Georgia Tech Research Corporation
Participants: CellFE, Inc., Celgene Corporation, Merck & Co., Inc., University of Iowa
The goal of this project is to provide a practical microfluidic method for transfection of therapeutic transgenes that are virus-free, GMP-compliant, scalable across a large range of cell counts, and capable of transgene delivery to different cell types. It will focus on T-cells and iPSCs due to their importance for cell therapy manufacturing, and will potentially provide the first non-viral platform for transgene transfection in cell product manufacturing from bench to final product using a single protocol.